Vance Vanier

Vance Vanier, M.D. is currently the V.P. of Global Commercial Operations for non invasive prenatal testing (NIPT) at Illumina. Dr. Vanier was the President of Verinata Health which was acquired by Illumina in early 2013 in one of the largest venture-backed molecular diagnostic exits in the last decade. Verinata’s product, a non-invasive blood test which can replace the need for amniocentesis in pregnant women, has revolutionized the field of obstetrics since its launch in 2012. Dr. Vanier’s responsibilities include scaling NIPT global revenue, marketing, health plan contracting, and clinical affairs. He has managed the rapid revenue growth of NIPT and the fastest health plan coverage adoption in the history of molecular diagnostics going from inception to over 180M covered lives in 18 months. Before Verinata, Dr. Vanier served as President and CEO of Navigenics, a preventative genomics company acquired by Life Technologies. Dr. Vanier joined Navigenics as Chief Medical Officer in 2008. He was appointed CEO in late 2009, subsequently raised three rounds of venture capital financing and brought on strategic investors and distribution partners including Procter & Gamble and Highmark. Prior to Navigenics, Dr. Vanier served as a partner in the life sciences practice at Mohr Davidow Ventures (MDV), a two billion dollar venture fund, where he invested in molecular diagnostic and online health businesses. Dr. Vanier received his M.D. from the Johns Hopkins School of Medicine and completed his residency training at the University of California, San Francisco, and Highland Hospital in Oakland. He received an M.B.A. from Stanford University, as well as dual bachelor’s degrees with honors. He continues to serve on the clinical faculty of Stanford Medical Center as an Assistant Clinical Professor. He was named a Henry Crown Fellow of the Aspen Institute in 2011 and recognized as one of San Francisco’s Top 40 Under 40 in 2012.